Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Hongfeng Gou"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Gastric cancer (GC) is a malignancy with poor prognosis and high heterogeneity. For HER2-positive, PD-L1 negative metastatic GC patients, chemotherapy plus trastuzumab is the first-line therapy. However, such patients soon acquired resistance to trea
Externí odkaz:
https://doaj.org/article/63758ce7d30040898acd93cd8a43bce0
Autor:
Qiancheng Hu, Nan Zhou, Hongfeng Gou, Shunyu Zhang, Xinchuan Chen, Qiyue Huang, Sirui Tan, Minggang Su
Publikováno v:
BMJ Open, Vol 14, Iss 4 (2024)
Introduction Accurate baseline clinical staging is critical to inform treatment decision-making for patients with gastric cancers. Peritoneal metastasis (PM) is the most common form of metastasis in gastric cancer and mainly diagnosed by diagnostic l
Externí odkaz:
https://doaj.org/article/48a59f2cff6d4cbda4023795bb6e967c
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22038-22046 (2023)
Abstract Background Fruquintinib has demonstrated significant improvement in overall survival (OS) among previously treated metastatic colorectal cancer (mCRC) patients. However, the utilization of fruquintinib has been constrained by various toxicit
Externí odkaz:
https://doaj.org/article/dec86540cc4e4b57945818b50db56fa8
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Biliary tract cancer (BTC) is a relatively rare but highly aggressive malignancy. However, there is currently no satisfactory second-line regimen for patients without specific genetic mutations. Nanoparticle albumin–bound paclit
Externí odkaz:
https://doaj.org/article/3b3841133de54b5aa701ddfc26ee55f7
Autor:
Li Tu, Weihan Zhang, Lu Ni, Zihan Xu, Kun Yang, Hongfeng Gou, Qing Zhu, Ming Liu, Yu Yang, Jiankun Hu, Meng Qiu
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4161-4169 (2023)
Abstract Background Intraperitoneal paclitaxel is proved to be efficient for peritoneal metastasis of gastric cancer. It remains uncertain the efficacy and safety of the triplets regimen which combined intraperitoneal high‐dose paclitaxel with syst
Externí odkaz:
https://doaj.org/article/60fc5110660c4329958b4c87f17e5a67
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Introduction The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for systematically identif
Externí odkaz:
https://doaj.org/article/478f270594e34b518441418c86f6fe88
Autor:
Nan Zhou, Yuhong Chen, Qian Huang, Lili Jiang, Hu Liao, Hongfeng Gou, You Lu, Guowei Che, Yan Zhang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immunotherapy plus chemotherapy has been approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC, stage IV). Recently, the 2023 version of the National Comprehensive Cancer Network Guidelines recommended immunotherapy
Externí odkaz:
https://doaj.org/article/bb3ec0033d1a4d65a68ab6424161fa8f
Autor:
Yihong He, Xin Zan, Junming Miao, Bilan Wang, Yin Wu, Yangmei Shen, Xinchuan Chen, Hongfeng Gou, Songping Zheng, Ning Huang, Yongzhong Cheng, Yan Ju, Xianghui Fu, Zhiyong Qian, Peizhi Zhou, Jiagang Liu, Xiang Gao
Publikováno v:
Materials Today Bio, Vol 16, Iss , Pp 100423- (2022)
Current treatment of glioma is hampered due to the physical blood-brain barrier (BBB) and the resistance to traditional chemotherapeutic agents. Herein, we proposed a combined treatment strategy based on Cyclo (Arg-Gly-Asp-d-Phe-Lys) (cRGDfk) peptide
Externí odkaz:
https://doaj.org/article/288292a33fb2463ba427b6f2b1da8c8c
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival
Externí odkaz:
https://doaj.org/article/376652bcf67046bbaa88238e37e72bfa
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundGallbladder cancer (GBC) is a fatal cancer, and the efficacy of the current standard second-line chemotherapy for GBC is limited. Novel therapies need to be explored. This retrospective analysis was aimed to investigate the outcomes of pati
Externí odkaz:
https://doaj.org/article/08b11ecda43f4b50a10d22e6f37ebaa5